Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Common Equity: 2020-2024

Historic Common Equity for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $153.1 million.

  • Prime Medicine's Common Equity fell 14.61% to $161.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.8 million, marking a year-over-year decrease of 14.61%. This contributed to the annual value of $153.1 million for FY2024, which is 15.09% up from last year.
  • As of FY2024, Prime Medicine's Common Equity stood at $153.1 million, which was up 15.09% from $133.1 million recorded in FY2023.
  • In the past 5 years, Prime Medicine's Common Equity registered a high of $316.3 million during FY2022, and its lowest value of -$156.2 million during FY2021.
  • Moreover, its 3-year median value for Common Equity was $153.1 million (2024), whereas its average is $200.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first slumped by 6,782.63% in 2021, then soared by 302.43% in 2022.
  • Prime Medicine's Common Equity (Yearly) stood at $2.3 million in 2020, then crashed by 6,782.63% to -$156.2 million in 2021, then spiked by 302.43% to $316.3 million in 2022, then tumbled by 57.92% to $133.1 million in 2023, then rose by 15.09% to $153.1 million in 2024.